Earnings ·
UroGen Pharma Ltd. reported second quarter 2026 financial results, announcing total revenue of $72.5 million compared…
URGNUroGen Pharma Ltd.
UroGen Pharma Ltd. reported second quarter 2026 financial results, announcing total revenue of $72.5 million compared to $24.2 million in the prior year period. ZUSDURI generated $50.4 million in net product revenue, reflecting 73% quarter-over-quarter growth, while JELMYTO contributed $22.0 million. The company reported a net loss of $14.4 million, or $0.28 per share, narrowing from the $49.9 million loss recorded in Q2 2025. UroGen increased its full-year 2026 operating expense guidance to a range of $260 million to $270 million and maintained JELMYTO revenue expectations between $97 million and $101 million. The firm remains on track for a third quarter NDA submission for UGN-103 and expects to initiate a Phase 1 trial for UGN-501 in the fourth quarter of 2026.